| Similar Articles |
|---|
 |
Bio-IT World
December 15, 2003
Mark D. Uehling |
Model Patient Despite the FDA's new support for computational modeling, the pharmaceutical industry remains cautious about simulating clinical trials.   |
Nursing Management
January 2012
Lawrence et al. |
Type 2 Diabetes: Growing to Epic Proportions Affecting all age groups and all aspects of a person's life, diabetes is a major public health issue worldwide, requiring lifelong behavioral and lifestyle changes and support. |
Nurse Practitioner
May 2011
Stacey A. Seggelke |
Hitting the target for inpatient glycemic management An understanding of glycemic treatment options for hospitalized patients is essential for good patient outcomes. |
Bio-IT World
June 17, 2004
John Russell |
Systems Biology - Now Leaving on Track 1 Entelos, a leader in predictive biosimulation, partners with pharmaceutical and biotech organizations worldwide to develop effective new treatments for disease. Michael French, chief business officer at Entelos, explains what powers the systems biology engine. |
Nursing
November 2009
Christine Kessler |
Glycemic control in the hospital: How tight should it be? Based on recent studies, the answer to that question remains controversial. This article will explore this issue and present current best practices for caring for a patient in the hospital who has diabetes or hyperglycemia. |
Chemistry World
August 23, 2013
Jessica Cocker |
Plant protein regulates diabetes treatment A plant protein has been used to make a new class of glucose-responsive polymer nanogels that could one day negate the need for diabetes patients to constantly monitor their blood glucose levels and inject themselves with insulin. |
Bio-IT World
October 2006
John Russell |
Entelos Makes Post IPO Report After netting $16.6 million in a public offering on London's Alternative Investment Market last April, biosimulator Entelos released interim six-month results. |
Bio-IT World
November 12, 2002
Michael Goldman |
A Virtual Pharmacopeia Computational modeling of disease pathways, organs --- even patients --- could transform drug discovery. Does salvation exist in silico? |
Pharmaceutical Executive
September 1, 2005
Mattingly & Saxberg |
Biomarkers Come of Age In the past five years, biomarkers have become an essential part of pharmaceutical R&D. Seven industry experts explain how it happened - and what comes next. |
The Motley Fool
June 3, 2011
Brian Orelli |
Tag-Teaming Melanoma for Fun and Profit Bristol-Myers Squibb and Roche hook up. |
Chemistry World
April 8, 2014
Sarah Kenwright |
Olive oil may offer diabetes protection Spanish scientists say increasing the amount of olive oil in your diet could reduce your risk of developing metabolic syndrome and type 2 diabetes. |
Bio-IT World
March 2006
John Russell |
It's All About the Drugs A conversation with biopharma Organon's executive VP for global research and development highlights how, regardless of the company's enthusiasm for new technology, it is first and foremost interested in pharmacology and medicinal chemistry -- drugs. |
Chemistry World
January 27, 2012
Sarah Houlton |
Illumina fends off Roche hostile bid Roche has made a $5.7 billion hostile bid for the genome sequencing company Illumina, after the San Diego, US-based company rejected its initial approach. |
Bio-IT World
February 2006
John Russell |
Marvelous Models of Biological Systems Here are highlights from a roundtable discussion with researchers representing academia and pharmaceuticals, as well as executives from modeling technology providers on whether or not Pharma is ready to bet on computational modeling of biological systems. |
Chemistry World
February 26, 2014
Ned Stafford |
Roche disputes unethical East German trial claims Clinical trials in the 1980s, performed in former communist East Germany by global pharmaceutical giant Hoffmann-La Roche, adhered to international standards and did not violate East German laws, according to a report issued by the company after a six month internal investigation. |
Bio-IT World
August 18, 2004 |
Project Summaries Drug Discovery and Development: Ace BioSciences... Compugen... Entelos/Organon... Iconix Pharmaceuticals... Johnson & Johnson Pharmaceutical Research & Development... Laboratoire Kastler Brossel ... etc. |
AskMen.com
Alex Santoso |
What You Should Know About Diabetes Not many men understand what diabetes is, why it's very bad for them (it is one of the leading causes of impotence), what they can do to avoid getting it or how to treat it. |
The Motley Fool
August 27, 2010
Brian Orelli |
Down 35%! This Just Shouldn't Happen Someone's to blame and it isn't ImmunoGen. |
Pharmaceutical Executive
July 1, 2005
Zaborowski, Hammer & Lawler |
Informatics Rules How global computer systems helped far-flung research centers at Roche work together |
American Family Physician
March 15, 2001
Goutham Rao |
Insulin Resistance Syndrome Insulin resistance can be linked to diabetes, hypertension, dyslipidemia, cardiovascular disease and other abnormalities. Because resistance usually develops long before these diseases appear, identifying and treating insulin-resistant patients has potentially great preventive value... |
The Motley Fool
October 17, 2006
Brian Lawler |
Roche Rocks The Swiss pharma has a stable of hot brands and lots of promise in the pipeline. Investors, this may be a pharmaceutical worth looking at. |
The Motley Fool
June 18, 2010
Brian Orelli |
Hot Dog! No Competition for Now Roche's diabetes pipeline drug is delayed. |
The Motley Fool
September 8, 2010
Brian Orelli |
You Must Realize This Drug Works by Now Vertex concludes its phase 3 trials with another win. |
Chemistry World
June 26, 2012
Sarah Houlton |
Roche rapped for side-effect reporting failure Roche has been rapped by the European Medicines Agency for failing to report a large number of potential drug side-effects. The UK's Medicines and Healthcare products Regulatory Agency identified deficiencies in the company's medicine safety reporting system. |
American Family Physician
September 15, 2006
Havas & Donner |
Tight Control of Type 1 Diabetes: Recommendations for Patients Physicians play an important role in helping type 1 diabetes patients make essential lifestyle changes to help reduce the risk of microvascular and macrovascular complications. |
BusinessWeek
October 22, 2009
Arlene Weintraub |
Tough Love, Lower Health Costs A UnitedHealthcare plan offers incentives to employees who strictly control their diabetes. |
Pharmaceutical Executive
May 1, 2009 |
The Fate of Mannkind Al Mann has sunk almost $1 billion of his own money into a new insulin delivery system. Will FDA be persuaded? |
The Motley Fool
February 12, 2010
Brian Orelli |
Don't Ignore This Potential Blockbuster Five trials later, Roche's diabetes drug taspoglutide seems like a winner. |
The Motley Fool
August 29, 2011
Brian Orelli |
Drug Approved for Few Patients -- but That's OK The age of personalized medicine is upon us. Earlier this month, the FDA approved Roche's melanoma drug Zelboraf for patients with a specific mutation in BRAF. And on Friday, the agency approved Pfizer's Xalkori for lung cancer patients that are ALK-positive. |
Bio-IT World
May 19, 2004
John Russell |
Seeing the Forest and the Trees A tiny clearing in the fog of systems biology. |
Pharmaceutical Executive
November 1, 2012
Sue Barrowcliffe |
Real World Insights Commercial teams as well as patients can benefit from managed access programs, which are designed to provide access to medicines outside of the clinical and commercial setting, for patients who have no other available treatment options. |
BusinessWeek
December 10, 2009
Weintraub & Wechsler |
The New Prominence of Comparative Drug Trials Pharmaceutical makers, once wary of head-to-head trials, now embrace them as marketing tools. |
Fast Company
January 2002
George Anders |
Roche's New Scientific Method How does a giant pharmaceutical company reckon with genomics technology? By making a fresh start in how it recruits its scientists, manages projects, and uses computers. Here's how the Roche Group is reinventing how it invents... |
The Motley Fool
December 11, 2009
Brian Orelli |
Roche and Biogen's Blockbuster Making Good Progress Roche and Biogen move their potential blockbuster through the clinical trial maze. |
Chemistry World
June 30, 2014
Phillip Broadwith |
Inhaled insulin approved in US Mannkind's Affreza is aimed at reducing the need for patients to inject themselves with insulin so frequently. |
Bio-IT World
March 8, 2005
John Russell |
Entelos' Lofty Aspirations This is an interesting period for systems biology's wing of predictive biology companies. The label's luster is fading, but buoyed by pharma's growing interest, they are trying to figure out how to grow. |
Chemistry World
February 2, 2015
Megan Tyler |
Shock tactics for drug delivery Scientists in India have developed a shock wave-based drug delivery system that could be used to administer insulin in diabetic patients and reduce the need for painful injections. |
BusinessWeek
November 25, 2009
Arlene Weintraub |
Can Roche Leave Genentech Alone? Now that Roche has acquired the biotech superstar, success will depend on keeping some distance. |
Pharmaceutical Executive
June 1, 2014
Ben Comer |
Take as Directed: From Force to Finesse in Promoting Adherence Healthcare players tout patient education and engagement as the keys to better drug adherence rates. Patients agree, as long as that translates to convenient and affordable access to therapy. |
Bio-IT World
September 2006
John Russell |
Predicting the Future of Systems Biology Buoyed by promising results from a recent collaboration with Pfizer on drug-induced vascular injury, Keith Elliston, CEO of modeling and biosimulation specialist Genstruct, offers a candid view of industry's flirtation with systems biology and the future prospects for the field. |
The Motley Fool
June 7, 2011
Brian Orelli |
Sometimes a Partnership Feels Personal Merck and Roche hook up for a diagnostic drug deal. |
Chemistry World
April 5, 2013
Phillip Broadwith |
Roche to release Tamiflu trial data Swiss pharma company Roche has finally agreed to give independent researchers access to data on all 74 clinical trials it ran on the antiviral influenza drug Tamiflu (oseltamivir). |
American Family Physician
January 1, 2003
Jennifer B. Marks |
Perioperative Management of Diabetes Diabetic patients who require surgery present special challenges in perioperative management. Special attention must be paid to prevention and treatment of metabolic derangements. |
AskMen.com
April 29, 2001
Joshua Levine |
Do You Have Diabetes? Diabetes is not contagious; people cannot "catch" it from one another. However, certain factors can increase one's risk of developing the disease... |
Chemistry World
January 28, 2015
Rebecca Trager |
Roche chases bolt-on acquisitions as it pushes into genomics A recent spending spree by Roche is intended to take advantage of emerging molecular information and genomic analysis, as the company anticipates that the field will play an increasingly important role for future medicines and diagnostics. |
Managed Care
May 2006
Fadia T. Shaya & Deshpande |
New Treatment Approaches To Diabetes The goal of diabetes management is maintaining glycemic control while targeting quality of life improvements. |
Chemistry World
March 8, 2007
Jessica Ebert |
How to Catch an Insulin-Doping Athlete A growing number of athletes reportedly take insulin to boost their performance illegally, but controlling insulin abuse has gone largely unchecked. Now, a urine test designed by German and Belgian scientists could be set to change all that. |
American Family Physician
August 1, 2004
Mayfield & White |
Insulin Therapy for Type 2 Diabetes: Rescue, Augmentation, and Replacement of Beta-Cell Function New insulin preparations and a better understanding of insulin physiology provide more options for family physicians attempting to effectively tailor insulin therapy to the needs of individual patients. |
The Motley Fool
June 21, 2011
Brian Orelli |
Data Look Good, Approval Unknown Accelerated approvals are like that. The data should give Curis' investors added confidence that vismodegib works, but whether it can get approved with this limited data remains to be seen. |
Chemistry World
June 22, 2015
Manisha Lalloo |
'Smart patch' set to deliver for diabetes patients A research team has created patches that release insulin in response to changes in oxygen brought about by high glucose levels and hope this could lead to a smarter, painless way of treating the disease. |
